Elinogrel

Elinogrel
Clinical data
Other names	PRT-060128
Routes of; administration	By mouth, IV
ATC code	None;
Legal status
Legal status	Development terminated;
Pharmacokinetic data
Metabolism	Mainly unchanged, ~15% N-demethylation[1]
Excretion	Urine, faeces
Identifiers
	IUPAC name N-[(5-Chlorothiophen-2-yl)sulfonyl]-N′-{4-[6-fluoro-7-(methylamino)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]phenyl}urea;
CAS Number	936500-94-6;
PubChem CID	16066663;
ChemSpider	17226246;
UNII	915Y8E749J;
KEGG	D09607;
CompTox Dashboard (EPA)	DTXSID50918262 ;
Chemical and physical data
Formula	C20H15ClFN5O5S2
Molar mass	523.94 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC1=C(C=C2C(=C1)NC(=O)N(C2=O)C3=CC=C(C=C3)NC(=O)NS(=O)(=O)C4=CC=C(S4)Cl)F;
	InChI InChI=1S/C20H15ClFN5O5S2/c1-23-15-9-14-12(8-13(15)22)18(28)27(20(30)25-14)11-4-2-10(3-5-11)24-19(29)26-34(31,32)17-7-6-16(21)33-17/h2-9,23H,1H3,(H,25,30)(H2,24,26,29); Key:LGSDFTPAICUONK-UHFFFAOYSA-N;

Elinogrel (INN,[2] USAN) was an experimental antiplatelet drug acting as a P2Y₁₂ inhibitor. Similarly to ticagrelor and in contrast to clopidogrel, elinogrel was a reversible inhibitor that acted fast and short (for about 12 hours), and it was not a prodrug but pharmacologically active itself. The substance was used in form of its potassium salt, intravenously for acute treatment and orally for long-term treatment.[3] Development was terminated in 2012.

History

The substance was originally developed by Portola Pharmaceuticals, with Phase II clinical trials conducted around 2008–2011.[4] In February 2009, Novartis bought worldwide rights to develop it further, intending to conduct Phase III studies and commercialise the drug.[5] The development of the drug was terminated in January 2012 by Novartis.[6]

References

Siller-Matula JM, Krumphuber J, Jilma B (February 2010). "Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases". British Journal of Pharmacology. 159 (3): 502–17. doi:10.1111/j.1476-5381.2009.00555.x. PMC 2828016. PMID 20050853.
"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 63" (PDF). World Health Organization. pp. 50–1. Retrieved 1 December 2016.
Gurbel PA, Kereiakes D, Tantry US (November 2010). "Elinogrel potassium: Receptor antagonist antiplatelet therapy". Drugs of the Future. 35 (11): 885–92. doi:10.1358/dof.2010.35.11.1529823 (inactive 2021-01-10).CS1 maint: DOI inactive as of January 2021 (link)
Michelson AD (2011). "Advances in antiplatelet therapy". Hematology. American Society of Hematology. Education Program. 2011: 62–9. doi:10.1182/asheducation-2011.1.62. PMID 22160013.
"Novartis gains worldwide rights to elinogrel, a Phase II anti-clotting compound with potential to reduce risk of heart attack". Insciences. Archived from the original on 2014-07-14.
"Novartis drops elinogrel outright". BioPortfolio. Archived from the original on 2012-07-29.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Siller-Matula JM, Krumphuber J, Jilma B (February 2010). "Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases". British Journal of Pharmacology. 159 (3): 502–17. doi:10.1111/j.1476-5381.2009.00555.x. PMC 2828016. PMID 20050853.

[INN-2] "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 63" (PDF). World Health Organization. pp. 50–1. Retrieved 1 December 2016.

[3] Gurbel PA, Kereiakes D, Tantry US (November 2010). "Elinogrel potassium: Receptor antagonist antiplatelet therapy". Drugs of the Future. 35 (11): 885–92. doi:10.1358/dof.2010.35.11.1529823 (inactive 2021-01-10).CS1 maint: DOI inactive as of January 2021 (link)

[4] Michelson AD (2011). "Advances in antiplatelet therapy". Hematology. American Society of Hematology. Education Program. 2011: 62–9. doi:10.1182/asheducation-2011.1.62. PMID 22160013.

[5] "Novartis gains worldwide rights to elinogrel, a Phase II anti-clotting compound with potential to reduce risk of heart attack". Insciences. Archived from the original on 2014-07-14.

[6] "Novartis drops elinogrel outright". BioPortfolio. Archived from the original on 2012-07-29.